Table 1. Patients characteristics and risk factors stratified by race/ethnicity.
NHW, non-Hispanic White; NHB, non-Hispanic Black; IQR, interquartile range. p <0.001, statistically significant.
| Total Population | NHW | NHB | Hispanics | Others | p-Value | |
| (N=6,079) | (n=4,156) | (n=571) | (n=1,352) | (n=441) | ||
| Median age (years) (IQR) | 66 (56-74) | 68 (59-76) | 64 (54-72) | 59 (48-70) | 66 (56-74) | <0.001 |
| Income | <0.001 | |||||
| Quartile I | 727 (11.2%) | 546 (13.1%) | 112 (196%) | 53 (3.9%) | 16 (4.0%) | |
| Quartile II | 1,578 (24.4%) | 1,109 (26.7%) | 165 (28.9%) | 251 (18.6%) | 53 (13.1%) | |
| Quartile III | 2,469 (38.1%) | 1,412 (34.0%) | 205 (35.9%) | 714 (52.9%) | 138 (34.2%) | |
| Quartile IV | 1,707 (26.3%) | 1,089 (26.2%) | 89 (15.6%) | 332 (24.6%) | 197 (48.8%) | |
| Stage | <0.001 | |||||
| Stage I | 1,851 (54.3%) | 1,222 (55.6%) | 175 (55.9%) | 333 (47.8%) | 121 (59.6%) | |
| Stage II | 669 (19.6%) | 431 (19.6%) | 48 (15.3%) | 155 (22.3%) | 35 (17.2%) | |
| Stage III | 564 (16.5%) | 348 (16.0%) | 50 (16.0%) | 135 (19.4%) | 31 (15.3%) | |
| Stage IV | 326 (9.6%) | 197 (9.0%) | 40 (12.8%) | 73 (10.5%) | 16 (7.9%) | |
| Metropolitan | <0.001 | |||||
| Non-Metro | 1,073 (16.6%) | 906 (21.8%) | 73 (12.8%) | 63 (4.7%) | 31 (7.9%) | |
| Metro I | 598 (9.2%) | 438 (10.5%) | 67 (11.7%) | 78 (5.8%) | 15 (3.8%) | |
| Metro II | 1,369 (21.2%) | 851 (20.5%) | 121 (21.2%) | 307 (22.7%) | 90 (23.0%) | |
| Metro III | 3,429 (53.0%) | 1,961 (47.2%) | 310 (54.3%) | 902 (66.8%) | 256 (65.3%) | |
| Surgery | 5,711 (89.4%) | 3,650 (89.1%) | 490 (87.5%) | 1,227 (91.6%) | 344 (87.5%) | 0.014 |
| Chemotherapy | 648 (10.0%) | 357 (8.6%) | 69 (12.1%) | 185 (13.7%) | 37 (9.2%) | <0.001 |
| Radiation | 535 (8.3%) | 317 (7.7%) | 48 (8.5%) | 142 (10.7%) | 28 (7.0%) | 0.006 |
| Marital status | <0.001 | |||||
| Married | 3,561 (60.6%) | 2,347 (62.4%) | 227 (43.7%) | 750 (59.7%) | 237 (71.0%) | |
| Single | 2,311 (39.4%) | 1,414 (37.6%) | 293 (56.4%) | 507 (40.3%) | 97 (29.0%) | |
| Primary cancers | 5,206 (80.3%) | 3,206 (77.1%) | 464 (81.3%) | 1,194 (88.3%) | 342 (84.7%) | <0.001 |
| Mortality | 1,447 (22.5%) | 901 (21.8%) | 155 (27.5%) | 321 ( 24.2%) | 70 (17.6%) | 0.001 |
| 5-year survival | 75.30% | 76.60% | 71.10% | 71.10% | 81.00% | <0.001 |
| 10-year survival | 71.10% | 72.50% | 64.20% | 67.10% | 78.10% | <0.001 |
| 15-year survival | 68.20% | 69.30% | 61.30% | 65.30% | 75.10% | <0.001 |